Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-ASC nanobody-based heavy chain antibody
- Development stage
- Preclinical
- Lead developer
- University Medical Center Hamburg-Eppendorf
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Parenteral
01
Overview
Anti-ASC nanobody-based heavy chain antibody is a preclinical-stage biologic being developed for the treatment of antibody-mediated autoimmune kidney diseases, such as membranous nephropathy. Developed by researchers at the University Medical Center Hamburg-Eppendorf, this therapeutic candidate consists of nanobody-based heavy chain antibodies (hcAbs) targeting a novel surface protein highly expressed on antibody-secreting cells (ASCs). By binding to this specific target, the hcAbs mediate potent cellular lysis of plasma and myeloma cells, leading to the depletion of pathogenic ASCs in the bone marrow and spleen. In preclinical models of experimental autoimmune membranous nephropathy (EAMN), treatment with these hcAbs significantly reduced antigen-specific antibody levels, decreased podocyte damage, and improved clinical outcomes.
- Other names
- anti-ASC hcAbanti-antibody-secreting cell heavy chain antibodyanti-antibody-secreting cell nanobody-based heavy chain antibody
Beyond the preview
Go deeper on anti-ASC nanobody-based heavy chain antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-ASC nanobody-based heavy chain antibody.